USD10
SRRK azioni
Informazioni su Scholar Rock HoldingScholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
USD10
SRRK azioni
Informazioni su Scholar Rock HoldingScholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Statistiche
FINESTRA DI NEGOZIAZIONE
Chiusa
APRE ALLE
Dati insufficienti
Capitalizzazione di mercato
5,13 Mld USD
PREZZO DI APERTURA
45,55 USD
MINIMO (1 anno)
22,71 USD
MASSIMO (1 anno)
49,82 USD
MINIMO (24H)
44,07 USD
MASSIMO (24 ore)
47,87 USD
VOLUME (24 ore)
3,29 Mln USD
12,27%
Cronologia dei prezzi
Time | Price | Change |
|---|---|---|
Oggi | 45,55 USD | |
1 giorno | 44,64 USD | 0,00% |
1 settimana | 39,18 USD | |
1 mese | 47,80 USD | |
1 anno | 33,81 USD |